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The H+-coupled transporter hPepT1 (SLC15A1) mediates the transport of di/tripeptides and many orally-active drugs across the brush-border
membrane of the small intestinal epithelium. Incubation of Caco-2 cell monolayers (15 min) with the dietary phosphodiesterase inhibitors caffeine
and theophylline inhibited Gly–Sar uptake across the apical membrane. Pentoxifylline, a phosphodiesterase inhibitor given orally to treat
intermittent claudication, also decreased Gly–Sar uptake through a reduction in capacity (Vmax) without any effect on affinity (Km). The reduction
in dipeptide transport was dependent upon both extracellular Na+ and apical pH but was not observed in the presence of the selective Na+/H+
exchanger NHE3 (SLC9A3) inhibitor S1611. Measurement of intracellular pH confirmed that caffeine was not directly inhibiting hPepT1 but
rather having an indirect effect through inhibition of NHE3 activity. NHE3 maintains the H+-electrochemical gradient which, in turn, acts as the
driving force for H+-coupled solute transport. Uptake of β-alanine, a substrate for the H+-coupled amino acid transporter hPAT1 (SLC36A1), was
also inhibited by caffeine. The regulation of NHE3 by non-nutrient components of diet or orally-delivered drugs may alter the function of any
solute carrier dependent upon the H+-electrochemical gradient and may, therefore, be a site for both nutrient–drug and drug–drug interactions in
the small intestine.
© 2007 Elsevier B.V. All rights reserved.Keywords: PepT1; Dipeptide transport; Na+/H+ exchange; NHE3; Intestinal absorption; Drug transport1. Introduction
The human intestinal H+-coupled di/tripeptide transporter
(hPepT1 or SLC15A1) is responsible for the transport of a
significant proportion of dietary protein across the brush-border
membrane of the small intestinal epithelium. hPepT1 is also of
pharmacological interest as it can transport orally-active drugs
such as β-lactam antibiotics and angiotensin converting enzyme
inhibitors [1–4]. More recently a number of amino acid mod-
ified pro-drugs such as val-acyclovir, L-DOPA-L-Phe and the
anti-hypotensive midodrine have been designed specifically to
target hPepT1 and thus to enhance oral bioavailability [3–5].
When expressed heterologously, hPepT1 functions as a Na+-
independent, pH-dependent, H+-coupled transporter [6,7].
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doi:10.1016/j.bbamem.2007.04.006di/tripeptide transport was via a Na+-coupled transport mech-
anism. Indeed, dipeptides can stimulate Na+ absorption in the
human small intestine and Na+ uptake in human intestinal Caco-
2 cell monolayers [8–10]. Ganapathy and Leibach proposed a
model to account for the interaction of H+-coupled di/tripeptide
transport and Na+ absorption [11] whereby the intracellular
acidification caused by di/tripeptide associated H+ influx
activated an apical Na+/H+ exchanger and thus Na+ absorption.
This model also explains the partial Na+-dependence of di/
tripeptide uptake observed in mammalian small intestine and
Caco-2 cell monolayers [11,12]. Inhibition of Na+/H+ exchange
by removal of extracellular Na+, prevents the enterocyte from
maintaining intracellular pH (pHi) during H
+/solute influx and,
therefore, abolishes the driving force (the transmembrane H+
electrochemical gradient) for further transport. The apical Na+/H+
exchanger specifically activated by di/tripeptide uptake is NHE3
(SLC9A3) which plays a significant role in Na+ absorption in the
small intestine [7,10,13].
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delivery it is important to elucidate how altering hPepT1
function may affect nutritional status and oral bioavailability.
Progress has been made in understanding how intestinal di/
tripeptide transport is regulated by hormonal and neural signals
as well as by disease states and surgical intervention (for review
see [14]). However, little is known about how co-administered
drugs or dietary factors affect hPepT1 function or the function
of other brush-border membrane transport proteins. Alteration
of cAMP levels within enterocytes by hormonal, neural and
paracrine signals is a key step in the regulation of many brush-
border membrane nutrient and electrolyte transporters. NHE3 is
inhibited acutely by increasing [cAMP]i [15]. Therefore, the
aim of this study was to identify how dietary and orally-
delivered compounds, which act as phosphodiesterase inhibi-
tors (and thus increase [cAMP]i by preventing breakdown),
affect hPepT1 function. The dietary phosphodiesterase inhibi-
tors caffeine and theophylline and the orally-delivered drug
pentoxifylline all inhibit dipeptide uptake across the brush-
border membrane of human intestinal epithelial Caco-2 cell
monolayers. This inhibition is not a direct effect on hPepT1 but
rather is indirect through inhibition of NHE3.
2. Materials and methods
2.1. Materials
Glycyl[1-14C]sarcosine (specific activity 57 mCi mmol−1)] was obtained
from Cambridge Research Biochemicals (Billingham, UK). [3-3H]β-Alanine
(specific activity 50 Ci mmol−1)] was obtained from American Radiolabeled
Chemicals (St. Louis, MO, USA). PACAP (pituitary adenylate cyclase-
activating polypeptide) was from Bachem (St. Helens, UK). Biotrak cAMP
enzyme immunoassay was from GE Healthcare (Chalfont St. Giles, UK). 2′,7′-
Bis(2-carboxyethyl-5(6)-carboxyfluorescein) acetoxymethyl ester (BCECF-
AM) was from Invitrogen (Paisley, UK). Transwell polycarbonate filters were
from Corning (Schiphol-Rijk, The Netherlands). S1611 was obtained from H.J.
Lang (Aventis Pharma Deutschland GmbH, Frankfurt/Main, Germany).
Forskolin, phosphodiesterase inhibitors, cell culture media and supplements
were from Sigma-Aldrich (Poole, UK). All other chemicals were from Sigma-
Aldrich or VWR (Lutterworth, UK) and were of the highest quality available.
2.2. Cell culture
Caco-2 cells (passages 100–119) were cultured as confluent monolayers on
permeable polycarbonate filters, as described previously [16]. Monolayers were
used at 14–22 days post-seeding and fed approximately 24 h prior to use.
2.3. Measurement of dipeptide uptake
[14C]Gly–Sar (0.5 μCi ml−1, 0.1 – 10 mM) or [3H]β-alanine (0.5 μCi ml−1,
0.1 mM) uptake across the apical membrane of Caco-2 cell monolayers was
measured, essentially as described previously [16]. Briefly, Caco-2 cells were
washed (in 4×500 ml) and bathed in modified Krebs' solution (composition
(mM): NaCl, 137; KCl, 5.4; MgSO4, 0.99; KH2PO4, 0.34; NaH2PO4, 0.3;
CaCl2, 2.8; Glucose, 10) or Na
+-free solution (identical except choline chloride
replaced NaCl and NaH2PO4 was omitted). Uptake was measured at apical pH
5.5 or pH 6.5 (10 mM MES, adjusted to the correct pH by Tris) with the
basolateral solution being pH 7.4 (10 mM HEPES, adjusted to the correct pH by
Tris) in all experiments. Uptake was measured over 15 min (37 °C) at the end of
which the monolayers were rinsed thoroughly (in 3×500 ml, ice-cold, pH 7.4
Krebs' solution). Various compounds were added to the buffers for the duration
of uptake (see figure legends for details). Cell monolayer-associated
radioactivity was determined by scintillation counting.2.4. Measurement of pHi
Intracellular pH (pHi) was measured in Caco-2 cell monolayers by
microspectrofluorimetry using the pH-sensitive dye BCECF, essentially as
described previously [10,17]. Cell monolayers were acidified by superfusion
with apical Gly–Sar (20 mM, 5 min) in modified Krebs' solution (Na+-free,
apical pH 5.5). The basolateral solution was Na+-free, pH 7.4 throughout all
experiments. pHi recovery was then measured in Na
+-containing pH 7.4 apical
solution until pHi returned to baseline. The monolayers were incubated with
caffeine (5 mM, apical and basolateral) for 10 min. The cells were then exposed
to Gly–Sar once again but in the continued presence of caffeine (thus total
exposure time to the compound before pHi recovery was 15 min). pHi recovery
was then measured in the continued presence of caffeine. The initial rate of pHi
recovery is expressed as H+ efflux calculated from the gradient of the first 30 s of
recovery [18].
2.5. Measurement of intracellular cAMP levels
Caco-2 cell monolayers were washed in 4×500 ml Krebs' solution (pH 7.4).
Monolayers were incubated for 15 min in the presence or absence of caffeine,
pentoxifylline, theophylline (all 5 mM), or forskolin (10 μM) at apical pH 6.5
and basolateral pH 7.4. Monolayers were then washed in 3×500 ml, ice-cold
Krebs' (pH 7.4) and lysed in 500 μl lysis buffer (from the Biotrak enzyme
immunoassay kit) for 10 min. [cAMP]i was measured following the kit protocol.
2.6. Statistical analysis
Data are expressed as mean±SEM unless stated otherwise. Statistical
comparisons of mean values were made using paired two-tailed Student's t-test
or one-way analysis of variance (ANOVA) (using the Tukey–Kramer or
Bonferroni's multiple comparisons post-test) as appropriate. Significance was
assumed if pb0.05. Curves were fitted using FigP software.3. Results
3.1. Inhibition of dipeptide uptake by caffeine is via inhibition
of NHE3
Uptake of the dipeptide Gly–Sar (glycylsarcosine) across the
apical membrane of Caco-2 cell monolayers was measured over
15 min at an apical pH (pH 6.5) representative of that found at
the surface of the proximal small intestine. Incubation of Caco-2
cell monolayers with the dietary phosphodiesterase inhibitor
caffeine (5 mM) at both the apical and basolateral surfaces (for
the duration of the 15 min uptake period) reduced Gly–Sar
uptake by around 50% (from 683.6±18.9 to 351.1±10.7 pmol
cm−2 [15 min]−1, n=17–18, pb0.001, Fig. 1A). Caffeine was
equally effective at inhibiting Gly–Sar uptake when added
solely to either the apical or basolateral chamber (data not
shown). Removal of extracellular Na+ reduces Gly–Sar uptake
(as described previously [12]) (Fig. 1A). However, in the
absence of extracellular Na+, caffeine had no effect on Gly–Sar
uptake (uptake being 244.0±9.1 and 242.0±9.5 pmol cm−2
[15 min]−1 in the absence and presence of caffeine respectively,
n=17–18, pN0.05).
Previously we have shown that the Na+-dependence of Gly–
Sar uptake can be attributed to a lack of NHE3 activity in the
absence of extracellular Na+ [10,12,18]. To test if the lack of
effect of caffeine in the absence of extracellular Na+ was due to
a requirement for NHE3 activity, dipeptide uptake was mea-
sured under other conditions where NHE3 would be inactive
Fig. 2. The effect of other phosphodiesterase inhibitors on dipeptide uptake. [14C]
Gly–Sar (100 μM, 0.5 μCiml−1) uptakewasmeasured (15min, 37 °C) across the
apical (pH 6.5) membrane of Caco-2 cell monolayers in the presence and absence
of extracellular Na+. (A) [14C]Gly–Sar uptake in the presence and absence of
theophylline (5 mM, both apical and basolateral) (n=6). ***pb0.001 vs. Na+
control; NS, pN0.05 vs. Na+-free control. (B) [14C]Gly–Sar uptake in the
presence and absence of pentoxifylline (5 mM, both apical and basolateral)
(n=12). ***pb0.001 vs. Na+ control; NS, pN0.05 vs. Na+-free control. (C) [14C]
Gly–Sar uptake in presence and absence of IBMX (1 mM, both apical and
basolateral, during the 15 min uptake and also for 1 h prior to uptake) and/or
PACAP (5 nM, basolateral only, present during 15 min uptake only) (n=12).
***pb0.001 vs. Na+ control; NS, pN0.05 vs. Na+-free control or vs. +PACAP
control as appropriate.
Fig. 1. The effect of caffeine on dipeptide uptake across the apical membrane
of Caco-2 cell monolayers. [14C]Gly–Sar (100 μM, 0.5 μCi ml−1) uptake was
measured (15 min, 37 °C) across the apical membrane of Caco-2 cell mono-
layers at apical pH 6.5 (unless stated otherwise) in the presence or absence of
caffeine (5 mM, both apical and basolateral). Under all conditions basolateral pH
was 7.4 (in the presence and absence of Na+, as appropriate). Results are
expressed as mean±SEM. (A) [14C]Gly–Sar uptake in the presence and absence
of extracellular Na+ (n=17–18). ***pb0.001 vs. Na+ control; NS, pN0.05 vs.
Na+-free control. (B) [14C]Gly–Sar uptake at either apical pH 6.5 or pH 5.5 and
in the presence and absence of the NHE3 inhibitor S1611 (3 μM, apical only)
(n=11–12). ***pb0.001 vs. −S1611 control; NS, pN0.05 vs. +S1611 control
or vs. pH 5.5 control as appropriate.
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(3 μM) significantly reduced Gly–Sar uptake in a manner
similar to that caused by the removal of extracellular Na+
( pb0.001). This concentration of S1611 is sufficient to inhibit
NHE3 completely but would not inhibit NHE2 or NHE1 [19].
Previous work has shown that in the absence of Na+, S1611 has
no effect on Gly–Sar uptake into Caco-2 cells [12]. In addition,
when hPepT1 is expressed in isolation in Xenopus laevis
oocytes, dipeptide uptake is not inhibited by S1611 [7]. This
observation confirms that the inhibition of dipeptide uptake by
S1611 into Caco-2 cells is an indirect effect via inhibition of
NHE3. In the presence of S1611, Gly–Sar uptake was no longer
inhibited by caffeine (5 mM). The level of inhibition caused by
caffeine alone, by S1611 alone and by both compounds together
were not significantly different ( pN0.05) suggesting that
caffeine and S1611 inhibit hPepT1 activity through a common
mechanism (i.e. NHE3 inhibition). Gly–Sar uptake increases
with decreasing apical pH, consistent with hPepT1 being a H+/
dipeptide symporter. However, NHE3 activity decreases with
acidification of the apical solution and is inactive by pH 5.5 due
to the unfavourable transmembrane pH gradient [12]. Previousstudies have shown that Gly–Sar uptake at apical pH 5.5 is not
inhibited by S1611 or by the removal of extracellular Na+
[7,12]. Similarly, Fig. 1B shows that caffeine (5 mM) has no
effect on Gly–Sar uptake at apical pH 5.5 ( pN0.05) suggesting
again that caffeine is inhibiting Gly–Sar uptake through
inhibition of NHE3.
Fig. 4. The effect of pentoxifylline on the concentration-dependent uptake of the
dipeptide Gly–Sar across the apical membrane of Caco-2 cell monolayers. [14C]
Gly–Sar (0.1–10 mM, 0.5 μCi ml−1) uptake was measured (15 min, 37 °C)
across the apical (pH 6.5) membrane of Caco-2 cell monolayers in the absence
(control, filled circles) and presence (open circles) of pentoxifylline (5 mM).
Lines are the best-fit curves for the hyperbolic Michaelis–Menten kinetics
(carrier-mediated (saturable) uptake following subtraction of the linear compo-
nent) fitted using FigP (r2=0.998 and 0.995 for control and +pentoxifylline,
respectively). Results are mean±SEM (n=6).
Fig. 3. Concentration dependent inhibition of dipeptide uptake by caffeine,
theophylline and pentoxifylline. [14C]Gly–Sar (100 μM, 0.5 μCi ml−1) uptake
was measured (15 min, 37 °C) across the apical (pH 6.5) membrane of Caco-2
cell monolayers in the absence and presence of caffeine (filled circles, 0.001–
25 mM), theophylline (open circles, 0.001–30 mM) or pentoxifylline (filled
squares, 0.001 – 30 mM). The results are presented as the percentage uptake in
Na+-containing conditions (after subtraction of uptake in Na+-free conditions).
Best-fit concentration response curves were fitted using FigP (r2=0.986, 0.994
and 0.996, for caffeine, theophylline and pentoxifylline, respectively). Data are
mean±SEM (n=6–12).
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is consistent with inhibition of phosphodiesterase activity
Phosphodiesterase inhibitors structurally-related to caffeine
and either found in diet (theophylline), or used as orally-
delivered therapeutics (pentoxifylline) or used as laboratory
tools (IBMX, 3-isobutyl-1-methylxanthine) were tested for
inhibition of hPepT1 (Fig. 2). Theophylline (5 mM, Fig. 2A),
pentoxifylline (5 mM, Fig. 2B) and IBMX (1 mM, Fig. 2C)
reduced dipeptide uptake in the presence of extracellular Na+
( pb0.001) but not in Na+-free conditions ( pN0.05). Previous-
ly, we have shown that the enteric neuropeptide PACAP
(pituitary adenylate cyclase-activating polypeptide) and the
related neuropeptide VIP (vasoactive intestinal peptide) reduce
dipeptide uptake across the apical membrane of Caco-2 cell
monolayers by inhibition of NHE3 [18]. PACAP activates the
VPAC1 receptor which is coupled to adenylate cyclase and,
therefore, increases [cAMP]i. Fig. 2C shows that when Caco-2
cell monolayers were incubated with PACAP (5 nM) in the
basolateral solution for the duration of uptake, Gly–Sar uptake
was reduced. Incubation of the cells with both PACAP and
IBMX resulted in a reduction in uptake which was not
significantly different from the uptake in the presence of either
PACAP or IBMX alone suggesting IBMX, like PACAP, is
inhibiting the NHE3-dependent component of Gly–Sar uptake.
Phosphodiesterase inhibitors increase the levels of cAMP
within cells by preventing cAMP breakdown. However, caffeine
can also elicit cell signalling effects such as antagonism of
adenosine receptors and activation of calcium release from
intracellular stores [20–22]. To confirm that the compounds
used in this study inhibit hPepT1 function through increasing
cAMP levels, [cAMP]i in Caco-2 cell monolayers was
measured. Monolayers were incubated with caffeine (5 mM),
theophylline (5 mM), pentoxifylline (5 mM) or the adenylatecyclase activator forskolin (10 μM) which can also inhibit
dipeptide uptake [12]. Cells were lysed and [cAMP]i measured
by enzyme immunoassay. Caffeine, theophylline and pentox-
ifylline caused [cAMP]i to more than double from control levels
of 950±230 fmol cm−2 (mean±SD, n=3) to 2200±830, 2780±
300 and 2330±150 fmol cm−2 (mean±SD, n=3), respectively.
However, the change in cAMP was modest compared to
[cAMP]i detected in the presence of forskolin (92500±
12990 fmol cm−2 [mean±SD, n=3]).
Inhibition of the Na+-dependent (NHE3-dependent) compo-
nent of Gly–Sar uptake by phosphodiesterase inhibitors was
concentration-dependent (Fig. 3). The IC50 values were 1.0±
0.2 mM for caffeine, 0.6±0.1 mM for theophylline and 0.5±
0.1 mM for pentoxifylline. The sensitivity of hPepT1 to these
compounds is consistent with the effect being through an
inhibition of phosphodiesterase activity [20,21,23–25]. At a
concentration of 5 mM all three phosphodiesterase inhibitors
almost completely inhibited Na+-dependent Gly–Sar uptake.
3.3. Pentoxifylline decreases the maximal capacity for
dipeptide uptake
Gly–Sar uptake across the apical membrane was measured at
apical pH 6.5 at various concentrations of Gly–Sar (Fig. 4). In
the presence of pentoxifylline (5 mM) Gly–Sar uptake was
reduced compared to control at all Gly–Sar concentrations.
Analysis of the Michaelis–Menten kinetics confirmed that the
maximal capacity (Vmax) for Gly–Sar uptake was significantly
reduced from 8246±913 to 5369±117 pmol cm−2 [15 min]−1
( pb0.05, n=6) by pentoxifylline but the affinity (Km) was not
affected (1.0±0.2 mM and 1.6±0.6 mM in the absence and
presence of pentoxifylline, respectively, pN0.05). Reduction in
the capacity for dipeptide uptake is consistent with a reduction
in the driving force (the H+-electrochemical gradient) for uptake
through inhibition of NHE3. Previously, we have shown that
Fig. 6. The effect of caffeine on amino acid uptake via hPAT1 across the apical
membrane of Caco-2 cell monolayers. [3H]β-Alanine (100 μM, 0.5 μCi ml−1)
uptake was measured (15 min, 37 °C) across the apical membrane of Caco-2 cell
monolayers at apical pH 6.5 in the presence or absence of Na+ and the presence
or absence of caffeine (5 mM, both apical and basolateral). Basolateral pH was
7.4 (in the presence and absence of Na+ and caffeine, as appropriate). Results are
expressed as mean±SEM (n=12). ***pb0.001 vs. Na+ control; NS, pN0.05 vs.
Na+-free control.
Fig. 5. Caffeine inhibits NHE3-mediated pHi recovery. Caco-2 cell monolayers
loaded with the pH-sensitive dye BCECF were allowed to equilibrate in Na+-
containing pH 7.4 solution before being exposed to Gly–Sar (20 mM) at the
apical membrane for 5 min in Na+-free, pH 5.5 solution (basolateral solution was
Na+-free, pH 7.4 throughout experiment). After removal of Gly–Sar, pHi
recovered rapidly back to baseline levels in Na+-containing pH 7.4 apical
solution. The monolayers were then incubated with caffeine (5 mM, both apical
and basolateral) for 10 min before Gly–Sar induced acidification and the
subsequent pHi recovery were again measured (in the continued presence of
caffeine). A. Representative trace showing the composite responses of a single
monolayer in the absence (Control) and presence (+Caffeine) of caffeine. The
horizontal bars identify the composition of the apical bathing solution. B. H+
efflux was calculated from the mean rate of change of pHi over the initial 30 s of
pHi recovery from Gly–Sar induced acidification in the presence (+Caffeine)
and absence (Control) of caffeine. Data are mean±SEM (n=4) and statistical
analysis was performed using Student's t-test: **pb0.01 vs. Control.
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uptake across the apical membrane of Caco-2 cell monolayers
[12].
3.4. Caffeine inhibits pHi recovery (NHE3 function) after
dipeptide-induced acidification
Previous work demonstrated that NHE3 (but not NHE1 or
NHE2) is selectively activated by the intracellular acidification
associated with H+/dipeptide symport in Caco-2 cell mono-
layers [10,12]. S1611, the removal of extracellular Na+, or
factors that increase [cAMP]i, such as forskolin and VIP, all
inhibit the ability of the cell to regulate pHi after H
+/solute-
induced intracellular acidification [10,12,18,26]. pHi was
measured using the pH-sensitive dye BCECF (Fig. 5). Caco-2
cell monolayers loaded with BCECF were superfused across theapical membrane with Na+-containing, pH 7.4 modified Krebs'
solution. The basolateral solution was maintained as Na+-free,
pH 7.4 solution throughout the experiment. Cells were exposed
to Gly–Sar (20 mM) under conditions where hPepT1 activity
would be maximal but where there would be no concurrent
NHE3 activity (pH 5.5, Na+-free). After 5 min, Gly–Sar had
induced a large intracellular acidification. When Gly–Sar was
removed and the apical solution returned to a Na+-containing,
pH 7.4 solution, pHi recovered rapidly back to baseline levels.
The same monolayers were then incubated with caffeine
(5 mM) in both the apical and basolateral solutions for
10 min. Gly–Sar was then reintroduced for 5 min in the
continued presence of caffeine. The degree and rate of
acidification caused by Gly–Sar was not altered by caffeine
suggesting that hPepT1 is not directly regulated by phospho-
diesterase inhibitors. However, the ability of the cell to recover
pHi after Gly–Sar-induced acidification was attenuated after the
15 min exposure to caffeine (Fig. 5A). The degree of attenuation
was quantified by calculating the H+ efflux rate over the first
30 s of pHi recovery (Fig. 5B). In the presence of caffeine H
+
efflux was reduced from 57.6±5.8 to 20.5±3.9 μM s−1 (n=4,
pb0.01).
To confirm that phosphodiesterase inhibitors do not have any
direct inhibitory effect on dipeptide transport, hPepT1 was
expressed in Xenopus laevis oocytes, as described previously
[7]. Incubation of hPepT1-expressing oocytes with phosphodi-
esterase inhibitors such as caffeine (5 mM) had no effect on
dipeptide uptake (data not shown).
3.5. Inhibition of NHE3 by caffeine also inhibits the H+/amino
acid transporter hPAT1 (SLC36A1)
The indirect nature of the inhibition of hPepT1 by
phosphodiesterase inhibitors suggests that any apical solute
transporter dependent upon the transmembrane H+-electro-
chemical gradient will similarly be regulated by these
compounds. The H+-coupled amino acid transporter hPAT1
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[27]. As well as mediating the uptake of a wide variety of amino
acids, hPAT1 can also transport orally-active drugs such as the
anti-epileptic vigabatrin [28]. Previously we have identified that
amino acid uptake into hPAT1-expressing oocytes is Na+-
independent but hPAT1-mediated amino acid uptake into Caco-
2 cells is partially Na+-dependent [26,29,30]. Intracellular
acidification caused by the hPAT1 substrate β-alanine selec-
tively activated Na+/H+ exchange by NHE3 [26]. Like H+-
coupled dipeptide uptake, H+-coupled amino acid uptake into
Caco-2 cells is inhibited by forskolin, S1611 and VIP in a Na+
and pH-dependent manner via inhibition of NHE3 [26,29,30].
Uptake of the hPAT1 substrate β-alanine [16] was measured
across the apical membrane of Caco-2 cell monolayers at apical
pH 6.5 for 15 min (Fig. 6). Caffeine (5 mM) reduced β-alanine
uptake in the presence ( pb0.001) but not the absence of
extracellular Na+ ( pN0.05) suggesting that H+-coupled amino
acid uptake via hPAT1 is also modulated indirectly through
regulation of NHE3.
4. Discussion
The di/tripeptide transporter hPepT1 acts as a high-capacity
route for solutes across the first barrier to oral-bioavailability,
the brush-border membrane of the small intestine. Many, orally-
active peptidomimetics and amino acid-conjugated pro-drugs
have been identified as hPepT1 substrates [3,4]. There is an
increasing number of examples of physiological regulation
(hormonal, neural, paracrine) of hPepT1 and of regulation
of hPepT1 in certain disease states and after surgery (re-
viewed by [14]). Another, less studied, factor which may affect
the degree to which drugs are absorbed across the small
intestinal epithelium is interaction with co-administered drugs
or components of diet. Exposure of Caco-2 cell monolayers to
the hPepT1 substrate Gly–Gln for 4 days resulted in a sub-
sequent increase in capacity for dipeptide uptake and in hPepT1
expression [31]. Another study found that an array of fla-
vonoids, which are found ubiquitously in foods of plant origin,
either inhibit, have no effect or increase the hPepT1-mediated
uptake of the antibiotic cefixime into Caco-2 cell monolayers
[32]. In this study we identify that incubation of human in-
testinal epithelial cells with either dietary or orally-active
therapeutic phosphodiesterase inhibitors reduces Gly–Sar
uptake through a reduction in hPepT1 capacity.
The data presented here show that the inhibition of Gly–Sar
uptake by phosphodiesterase inhibitors is both Na+- and pH-
dependent (Figs. 1 and 2) suggesting that inhibition is not a direct
effect on hPepT1 but rather through NHE3. When NHE3 is
inhibited (e.g. by the removal of extracellular Na+ or by addition
of S1611) the cells are no longer able to maintain pHi during
solute-induced acidification and, therefore, the driving force (the
transmembraneH+ electrochemical gradient) for further dipeptide
uptake is reduced. Previously, we have shown that hPepT1 can be
inhibited by other factors which are known to increase cAMP in
intestinal epithelial cells such as the enteric neuropeptides VIP
and PACAP [18]. Although caffeine, theophylline and pentoxifyl-
line can elicit effects through pathways other than increasingcAMP, a number of factors suggest that they are acting here as
phosphodiesterase inhibitors. Firstly, incubating Caco-2 cell
monolayers with all three compounds produced an increase in
[cAMP]i. The increase is relatively small compared to that
produced by forskolin. However, this could be due to the cAMP
signal being compartmentalised (as demonstrated in cardiomyo-
cytes [33]) and thus the local changemay bemuch greater than the
measured, global change. Secondly, phosphodiesterases can also
regulate the levels of cGMP but none of the compounds tested
here produced a significant change in [cGMP]i (data not shown).
Lastly, the concentrations of caffeine, theophylline and pentox-
ifylline required to produce inhibition of hPepT1 (IC50=1.0, 0.6
and 0.5 mM, respectively, Fig. 3) are much closer to those for
inhibition of phosphodiesterases than for other effects such as
antagonism of adenosine receptors (IC50≈2–80 μM) and release
of intracellular calcium (EC50≈5–20 mM) [20–22,34–36].
Theophylline (100 μM) has been shown to abolish increased
glucose absorption resulting from activation of A2 receptors by
luminal adenosine (5 mM) in mouse small intestine in vivo [37].
However, in addition to the significantly higher affinity for
theophylline, A2 receptors are positively coupled to adenylate
cyclase so antagonism of the receptor should cause a decrease in
[cAMP]i and not the increase noted here [22,37].
Caffeine (and to a lesser extent theophylline) is found in high
levels in many beverages either naturally or by addition. For
example, the average cup of coffee contains 85 mg of caffeine
[38]. Pentoxifylline is given orally as 400 mg tablets to treat
intermittent claudication as part of peripheral arterial disease
[39]. Although it is difficult to predict the actual concentration
at the surface of the small intestinal epithelium it is conceivable
that caffeine and pentoxifylline may reach concentrations high
enough to elicit an effect on hPepT1 similar to that measured
here using Caco-2 cell monolayers. There is evidence that
caffeine given orally in doses equivalent to diet can elicit
changes in small intestinal function. A study using human
volunteers found that ingestion or intraluminal jejunal perfusion
of caffeine (75–300 mg) caused a rapid reversal of net fluid
absorption to net secretion [40]. Although the cell signalling
pathway by which caffeine stimulated fluid secretion was not
investigated, this study does indicate that the concentrations of
caffeine used here in vitro may be sufficient to cause changes in
the small intestinal epithelium in vivo.
Since the initial reports of phosphodiesterase activity it has
become evident that there are many types of phosphodiesterase.
Currently there are 11 different PDE families each of which can
contain several isoforms and splice variants [24,41]. Many of
these isoforms are tissue or cell-specific and recent studies have
shown that they can be expressed in distinct sub-cellular locations
where they act to limit site, amplitude and duration of cyclic
nucleotide signals [24,33]. Little is known about which PDE
isoforms are found in the small intestinal epithelium. Studies
reporting tissue distribution of PDE mRNA expression often
include a small intestinal sample but generally it is not clear
whether the PDE is expressed specifically in enterocytes. A single
study of PDE3 isoforms identified that PDE3B but not PDE3A
mRNA was highly abundant in the epithelium and underlying
smooth muscle layers of developing small intestine of rat [42].
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inhibit all PDE isoforms with roughly equal efficacy [25,43,44].
However, since many PDE isoforms and variants are located in
distinctive cell and sub-cellular locations they are now considered
to be good targets for specific therapeutic agents. Often the re-
sulting drugs are given orally, for example, the PDE5 inhibitor
sildenafil used to treat erectile dysfunction [45]. PDE5 is expressed
at the mRNA level in the small intestine [46,47]. Further work is
required to identify which PDE isoforms are expressed in small
intestinal epithelial cells both along the proximal–distal and
crypt–villus axes and which isoforms play a functional role in
regulating solute transport at the brush-border membrane.
In conclusion, we have shown that non-nutrient components of
diet and orally-delivered therapeutic agents both regulate activity
of the nutrient and drug transporter hPepT1. This regulation is an
indirect effect through inhibition of apical NHE3 function, which
acts as a pHhomeostatic mechanism duringH+-coupled dipeptide
transport. Functional cooperativity between hPepT1 and NHE3
results not only in the absorption of di/tripeptides but also
stimulation of Na+ absorption [8–10]. The H+-coupled amino
acid transporter hPAT1 (SLC36A1) is regulated by caffeine in a
similar, indirect manner to hPepT1 (Fig. 6). Thus, through
modulation of a single homeostatic mechanism (NHE3), a
luminal compound may influence several different absorptive
mechanisms. The results presented here suggest that any
regulation of NHE3 activity by luminal contents, co-administered
drugs or by neurohormonal signals may have significant impact
on the general absorptive state of the cell. Any other nutrient
transporter dependent on the maintenance of the H+ electrochem-
ical gradient for function may be regulated in a similar manner.
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